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Abstract: The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health
problem throughout Latin America. Current therapeutic options are characterised by limited efficacy,
long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised
by gaps in our knowledge of disease pathogenesis, parasite biology and drug activity. Nevertheless,
several factors have come together to create a more optimistic scenario. Drug-based research has
become more systematic, with increased collaborations between the academic and commercial sectors,
often within the framework of not-for-profit consortia. High-throughput screening of compound
libraries is being widely applied, and new technical advances are helping to streamline the drug
development pipeline. In addition, drug repurposing and optimisation of current treatment regimens,
informed by laboratory research, are providing a basis for new clinical trials. Here, we will provide
an overview of the current status of Chagas disease drug development, highlight those areas where
progress can be expected, and describe how fundamental research is helping to underpin the process.
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1. Introduction
Chagas disease is endemic in many areas of Latin America, and is a particular problem
amongst the rural poor, where an estimated 6–7 million people are infected with the causative
agent, the protozoan parasite Trypanosoma cruzi [1]. The disease has also become a global health
problem, with several hundred thousand infected individuals within migrant populations, mainly in
the USA and Europe [2,3]. The principal route of T. cruzi infection is via hematophagous triatomine
bugs, although oral (contaminated food and drink) and congenital transmission are also important,
along with blood transfusion and organ transplantation. Encouragingly, public health measures,
specifically insecticide spraying of poor-quality housing, have had a significant impact in breaking
transmission cycles in some areas [4,5], but the infection is a zoonosis, and these measures will have to
be sustained to maintain this improved situation. Eradication by this route is unlikely to be feasible.
There are no vaccines against Chagas disease, and given the immunological complexity and long-term
nature of the infection, progress in this area is uncertain. Therefore, new drugs, which avoid the
drawbacks associated with the current therapeutic options, will have the potential to play a significant
role in eliminating the massive disease burden that results from this infection, and in reducing the
resulting constraints on the socio-economic development of many rural communities. The economic
impact associated with Chagas disease is more than $7 billion per annum, a figure exceeding the total
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global costs linked to uterine, cervical and oral cancers [6,7]. For further comparison, the estimated
productivity gains from elimination of lymphatic filariasis, schistosomiasis and soil-transmitted
helminths from the Americas would amount to approximately $0.5 billion per annum [8].
T. cruzi is an obligate intracellular parasite with an extremely wide mammalian host range, and an
ability to infect the vast majority of nucleated cells. Typically, transmission occurs when infected faeces
from the insect vector are deposited near the bite wound after a blood-meal. Flagellated metacyclic
trypomastigote forms of the parasite are then introduced via the wound or mucous membranes, by
scratching or rubbing. Following host cell invasion, trypomastigotes escape from the parasitophorous
vacuole into the cytoplasm, differentiate into the small rounded amastigote form, and replicate by binary
fission. Four to five days later, after several rounds of division, and differentiation into bloodstream
trypomastigotes, lysis of the host cell results in parasite release and dissemination of the infection.
In humans, the initial acute stage of the disease lasts 4–6 weeks, and is associated with patent
parasitemia and infection of most tissues and organs. However, symptoms are usually mild and
non-specific, with transient fever and muscle pain; the majority of individuals are unaware that they
have been infected. In some cases, the disease can be more serious, particularly in children, where death
can result from myocarditis or encephalopathy. Control of the infection is mediated predominantly by
a strong CD8 + T cell response, which reduces the parasite burden by 2–3 orders of magnitude [9,10],
although sterile immunity is rarely achieved. The disease transitions to an asymptomatic chronic stage,
where the parasite burden is low and focal. Despite the life-long nature of the infection, the majority
of individuals do not develop overt pathology, although a significant minority (~30%) progress to
a symptomatic chronic state characterised by progressive cardiac and/or digestive disease. In most
cases, this takes decades to become apparent. Cardiomyopathy is the most serious outcome of T. cruzi
infection [11,12], and in many areas of South America it is a major cause of heart disease. The digestive
symptoms, which include megaoesophagus and megacolon, also have serious consequences and can
require surgery to alleviate the symptoms [13].
2. The Current Status of Chagas Disease Chemotherapy
For the last 50 years, the orally-administered compounds benznidazole and nifurtimox have
remained the only drugs available to treat T. cruzi infections [14,15]. However, they require long-term
periods of administration (typically 60 days), are often noncurative (generally in the range 10–30% of
cases), toxicity is a significant problem, and use during pregnancy is contraindicated [16–18]. Side
effects are reported in up to 90% of patients, with cutaneous, digestive and neurological complications
being the most common [19]. As a result, patient compliance can be a major issue. Furthermore,
because only a minority of cases are diagnosed in the acute or asymptomatic chronic stages, the number
of T. cruzi-infected individuals offered antiparasitic drug treatment is relatively small [20,21].
Benznidazole and nifurtimox are nitroheterocyclic compounds, containing a nitro group attached
to imidazole and furan rings, respectively (Figure 1A,B). They function as prodrugs and are
bioactivated within the parasite by the same mitochondrial-localised flavin-dependent enzyme,
the type 1 nitroreductase TcNTR-1 [22,23]. It is the substrate-specificity of TcNTR-1 and the lack
of a corresponding enzyme in the mammalian host that accounts for the selectivity of drug action.
Reductive drug metabolism generates a series of reactive intermediates that have trypanocidal
activity, most notably glyoxal in the case of benznidazole [24], and an unsaturated open-chain
nitrile with nifurtimox [25] (Figure 1A,B). For benznidazole, drug-induced mutagenesis has been
identified as a possible mode of action, resulting, for example, in disruption to DNA-repair mechanisms,
and chromosome instability [26–30]. Possible inducers of mutagenesis include reactive drug metabolites,
enhanced oxidative stress resulting from drug adduct interactions with trypanothione, and the
production of 8-oxo-guanine and other oxidised nucleotides.
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Figure 1. Nitroaromatic drugs used to treat Trypanosoma cruzi infections, or undergoing clinical trial. 
(A) Reductive metabolism of benznidazole, initiated by TcNTR-1, leads to the production of an 
unstable hydroxylamine derivative. This is readily converted to a hydroxy intermediate (possibly 
through a nitrenium ion form), which then reacts with water to generate a dihydro-dihydrooxy. This 
slowly breaks down to release the highly reactive dialdehyde, glyoxal (circled in red) [24]. The 
intermediaries and final product can form adducts with proteins, DNA, and small molecules such as 
glutathione and trypanothione. (B) Nifurtimox is reduced by TcNTR-1, leading to the generation of 
an unstable hydroxylamine. This decomposes, potentially via a ketoxime intermediate, to form 
unsaturated (circled in red) and then saturated open-chain nitriles [25]. The unsaturated form 
mediates trypanocidal activity. (C) Fexinidazole, an NTR-1-activated 5-nitroimidazole prodrug [31], 
has recently been approved as an oral treatment for African trypanosomiasis [32,33]. It outperforms 
other nitroaromatic drugs as a curative treatment for experimental T. cruzi infections [34], and is 
undergoing clinical trial against Chagas disease [35]. 
Cross-resistance to both benznidazole and nifurtimox can be readily generated in vitro, often 
resulting from reduced expression of functional TcNTR-1 that impacts on the ability of the parasite 
to reduce nitro-drugs [22,36,37]. Given the relatively small numbers of patients who are actually 
drug-treated [20,21], the infrequency with which genetic exchange occurs in T. cruzi, and the 
extensive animal reservoir of the parasite, it is unlikely that acquired drug-resistance will develop or 
spread widely at a population level. However, natural parasite populations do display a broad range 
of susceptibility to benznidazole [36,38,39], a factor that could have a role in some treatment failures. 
The level of sensitivity in natural strains is not obviously associated with specific parasite lineages, 
and not linked to polymorphisms in the TcNTR-1 gene, suggesting that other processes could be 
involved. These might include alternative drug-activation enzymes [40], enhancement of oxidative 
defence [41] or DNA repair pathways [29], increased drug efflux [42] or decreased drug uptake. In 
addition, it has been observed that within infected cells, small numbers of the amastigote population 
can enter a state of apparent dormancy in which they display increased drug tolerance [43]. In the 
absence of new treatments, it is important that these alternative mechanisms are explored further to 
optimise the usage of the current drugs. 
Chronic chagasic heart disease is characterised by inflammation, fibrosis, blood clots and 
arrhythmias, which lead to progressive cardiac failure, and in some cases sudden death [44,45]. It is 
now generally accepted that the presence of the parasite is a prerequisite for driving the development 
of this pathology [46,47], although persistent infection of the target organs may not be essential. 
Rather, cumulative collateral damage could result from localised inflammatory immune responses 
generated against continuous rounds of reinfection by parasites trafficked from other more 
immunotolerant sites of persistence. Importantly, the central role played by the parasite in disease 
pathogenesis strongly implies that effective therapy should block or reduce the development of 
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(A) Reductive metabolism of benznidazole, initiated by TcN R-1, leads to the production of a unstable
hydroxylamine derivative. This is readily converted to a hy roxy inte med a (possibly through a
nitreni m io form), which then reacts with water to generate a dihydro-dihydrooxy. This slowly
breaks down to release the highly reactive dialdehyde, glyoxal (circled in red) [24]. The intermediaries
and final product can form adducts with proteins, DNA, and small molecules such as glutathione
and trypanothione. (B) Nifurtimox is reduced by TcNTR-1, leading to the generation of an unstable
hydroxylamine. This decomposes, potentially via a ketoxime intermediate, to form unsaturated (circled
in red) and then saturated open-chain nitriles [25]. The unsaturated form mediates trypanocidal activity.
(C) Fexinidazole, an NTR-1-activated 5-nitroimidazole prodrug [31], has recently been approved as
an oral treatment for African trypanosomiasis [32,33]. It outperforms other nitroaromatic drugs as
a curative treatment for experimental T. cruzi infections [34], and is undergoing clinical trial against
Chagas disease [35].
Cross-resistance to both benznidazole and nifurtimox can be readily generated in vitro, often
resulting from reduced expression of functional TcNTR-1 that impacts on the ability of the parasite
to reduce nitro-drugs [22,36,37]. Given the relatively small numbers of patients who are actually
drug-treated [20,21], the infrequency with which genetic exchange occurs in T. cruzi, and the extensive
animal reservoir of the parasite, it is unlikely that acquired drug-resistance will develop or spread
widely at a population level. However, natural parasite populations do display a broad range of
susceptibility to benznidazole [36,38,39], a factor that could have a role in some treatment failures.
The level of sensitivity in natural strains is not obviously associated with specific parasite lineages,
and not linked to polymorphisms in the TcNTR-1 gene, suggesting that other processes could be
involved. These might include alternative drug-activation enzymes [40], enhancement of oxidative
defence [41] or DNA repair pathways [29], increased drug efflux [42] or decreased drug uptake.
In addition, it h s been observe that with infe ted cells, m ll umbers of the amastigote population
can enter a state of apparent dor ancy in whic they display increased drug tolerance [43]. In the
absence of new treatments, it is important that these alternative mechanisms are explored further to
optimise the usage of the current drugs.
Chronic chagasic heart disease is characterised by infla mation, fibrosis, blood clots and
arrhythmias, which lead to progressive cardiac failure, and in some cases sudden death [44,45]. It is
now generally accepted that the presence of the parasite is a prerequisite for driving the development
of this pathology [46,47], although persistent infection of the target organs may not be essential. Rather,
cumulative collateral damage could result from localised inflammatory immune responses generated
against continuous rounds of reinfection by parasites trafficked from other more immunotolerant
sites of persistence. Importantly, the central role played by the parasite in disease pathogenesis
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strongly implies that effective therapy should block or reduce the development of pathology. Evidence
supporting this has come from several reports on the beneficial effects of curative treatment of acute
stage infections in experimental models [48–52]. Studies, using highly sensitive in vivo imaging, further
suggest that the beneficial outcomes, in terms of protection against cardiac pathology, may be lessened
if treatment is withheld until chronic stage symptoms develop [53]. In humans, the evidence suggests
that curative treatment of acute-stage infections also provides long-term therapeutic efficacy [54], with
a gradual diminution of benefit if treatment is delayed. Much of the cardiac damage in chronic patients
seems to be irreversible once it has developed. For example, in the BENEFIT study, no significant
improvements in cardiac function were observed in chronic chagasic patients 5 years after benznidazole
treatment [55]. In this clinical trial, volunteers had been preselected on the basis that they already
displayed cardiac disease, a decision that has provoked some discussion [56–58]. Taken together,
the current evidence supports the premise that early curative treatment of T. cruzi infections will have
optimal benefit in preventing the development of symptomatic cardiac pathology and other outcomes.
More recently, the BENDITA phase II clinical trial, carried out in Bolivia under the auspices
of the Drugs for Neglected Diseases initiative (DNDi), has investigated the impact of reducing the
benznidazole treatment period from 8 weeks to 2 weeks, and the dose from 300 mg/day to 150 mg [59].
In both cases, the curative rate (~80%) was similar to that in those who received the standard regimen,
and was accompanied by a reduction in the number of patients who discontinued treatment because
of drug toxicity. Although these findings are preliminary, they highlight the potential for minimising
the side effects of benznidazole, maintaining antiparasitic efficacy and removing some of the barriers
to successful treatment.
3. Progress in Chagas Disease Drug Development
Both target-based and phenotypic screening approaches have been widely applied to Chagas
disease drug-discovery. In the case of the former, there are an increasing number of enzymes
and metabolic pathways that have been genetically and/or chemically validated, and these have
been the focus of much research. For example, in T. cruzi, as in fungi, ergosterol is a major and
essential component of cell membranes, and inhibitors of its biosynthetic pathway have been prime
candidates for drug development [60,61]. Azoles, which act through inhibition of lanosterol 14-α
demethylase (CYP51), are effective antifungal agents [62], and attempts to repurpose several of
these for use against T. cruzi infections have generated considerable interest. Most prominently,
the antifungal drug posaconazole, a highly efficient inhibitor T. cruzi CYP51, showed great promise
in preliminary studies and was advanced into clinical trial. However, it was found to have limited
curative potential as a monotherapy, and provided no added benefit when used in combination with
benznidazole [63,64]. Similarly, the related triazole ravuconazole also performed sub-optimally in
clinical trial [65]. These failures were a great disappointment to the Chagas disease research community.
More recent studies have demonstrated that although posaconazole has an in vitro EC50 in the low
nanomolar range, a subpopulation of parasites seem refractory to drug activity, a phenomenon that
shows great variability between strains [66]. Furthermore, in vivo experiments have revealed that
posaconazole has limited ability to confer sterile cure on murine models, despite an initial pronounced
knockdown in the parasite burden [67,68]. Understanding why cytostatic drugs like posanconazole
struggle to eliminate T. cruzi infections will be critical to inform the drug development process. An
unexpectedly high number of “hits” obtained from phenotypic screens have been found to be inhibitors
of CYP51, perhaps reflecting features of the active site of the enzyme [69]. Given the failure of
posaconazole in clinical trials and a desire to focus on alternative targets, small molecule ligands with
CYP51 inhibitory properties are now actively excluded from further progress along drug development
pipelines [70].
Proteases have been successful drug targets in several pathogens, and members of the
cruzipain family of T. cruzi cysteine proteases have been intensively studied in this context [71,72].
Cruzipain functions in a wide variety of roles throughout the parasite life-cycle, including host cell
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invasion, differentiation, evasion of the immune response, and in several aspects of host–parasite
interaction [73–76]. The enzyme family has been subject to intense biochemical and structural scrutiny,
with inhibitors from several chemical classes having been shown to have potent trypanocidal properties
and promising in vivo activity, with treatment outcomes that include parasitological cure and reduction
of cardiac pathology [77–79]. Although none of these have yet progressed to clinical trial, parasite
cysteine proteases remain a research area with some promise. The parasite oxidative defence pathway
has also been an important focus of drug-related research. Many components and pathways display
parasite-specific features and have been genetically validated [80,81]. For example, the unique thiol
trypanothione (a glutathione:spermidine conjugate) plays a central role in maintaining redox balance
within the parasite [82–84]. The key enzyme trypanothione reductase (TR) has been widely targeted for
drug design, a process that has benefitted considerably from the availability of a crystal structure [85].
Other potential drug targets that have been investigated in T. cruzi and related parasites include
methionyl-tRNA synthetase [86] and enzymes involved in glycoconjugate biosynthesis [87].
Despite the widespread application of rational drug design, few new compounds identified
by this approach have yet advanced far along the Chagas disease drug development pipeline.
This has renewed interest in exploring the potential of other nitroaromatics that might have superior
properties to benznidazole and nifurtimox, even though they may share a common mechanism
of bioactivation, mediated by TcNTR-1. The recent approval of fexinidazole (Figure 1C) by the
European Medicines Agency as an oral treatment for African trypanosomiasis caused by Trypanosoma
brucei gambiense [32,33] has further strengthened this interest. Fexinidazole, an NTR-1-activated
5-nitroimidazole pro-drug [31], has been shown to outperform both benznidazole and nifurtimox
as a curative treatment for experimental T. cruzi infections [34] (Figure 2A,B, as example), and a
clinical trial to assess efficacy and tolerability against patients with asymptomatic chronic infections
has been undertaken [35]. In addition, there have also been a number of recent studies reporting
encouraging preliminary data on the antiparasite activities of other novel nitroaromatics [88], and of a
new generation of diverse organometallic compounds [89–92].
Probably the most prominent recent development in Chagas disease drug research has been the
increased use of high-throughput phenotypic screening [93–95]. The requirement for large compound
libraries, robotic sample handling equipment, expertise in parasite biology, and over-arching funding
mechanisms has brought together both the academic and commercial sectors, with not-for-profit drug
development agencies, such as the DNDi. These consortia are international in make-up and encompass
large research teams and networks with expertise in medicinal chemistry, pharmacology, toxicology,
molecular biology, biochemistry, and clinical sciences. Examples of such collaborative partnerships
include the GSK and Tres Cantos Open Lab Foundation; initiatives such as the kinetoplastid boxes, each
with ~ 200 chemical hits, which have been made freely available to the research community [96]; and the
Novartis-led project that identified the parasite proteasome inhibitor GNF6702, which has broad
spectrum anti-kinetoplastid activity [97]. This breakdown of drug-development into its component
parts has brought a more systematic approach to the process and has offered economies of scale that
are particularly important when the research area is drugs for neglected diseases.
The failure of posaconazole in clinical trial identified the urgent need for improved preclinical
methodologies with greater predictive power. One response has been the development of long-term
washout experiments, which demonstrated that even with prolonged posaconazole exposure
in vitro [98], there is an inability to kill all parasites. This is indicative of phenotypic heterogeneity
within the population, and perhaps the presence of a metabolically quiescent sub-group that is more
resistant to drug activity [43]. These findings further highlight where gaps in our understanding of
parasite biology can impact negatively on drug development. For the remainder of this review, we
will discuss how improvements in imaging procedures applied to predictive murine models have
allowed some of these issues to be addressed, and have helped to streamline aspects of the drug
screening process.
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Figure 2. Fexinidazole outperforms benznidazole and nifurtimox as a treatment for experimental 
Trypanosoma cruzi infections. (A) BALB/c mice were infected with bioluminescent T. cruzi CL Brener 
strain [99]. At the chronic stage of infection (124 days), they were treated with benznidazole (BNZ) or 
fexinidazole (FXN) (30 mg/kg, orally, once daily) for 5 days (marked by red arrow). Treated mice were 
immunosuppressed on days 138, 142 and 146 using cyclophosphamide (200 mg/kg, i.p) (red lines). 
Images were acquired using the Lumina II IVIS system (Caliper Life Science) [100]. (B) BALB/c mice 
at the acute stage of infection (15 days) were treated with nifurtimox (NFX) or FXN (100 mg/kg, orally, 
once daily) for 10 days (red arrow), and then immunosuppressed on days 35, 39 and 43 using 
cyclophosphamide (red line). UT, untreated control mice. Heat-maps are on log10 scales and indicate 
intensity of bioluminescence from low (blue) to high (red). Full data set available in reference [34]. 
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Mice have been widely used as experimental models in Chagas disease drug research. However, 
during the chronic stage of infection, which is the main target for new therapeutics, the parasite 
burden is extremely low, the sites of infection are highly localised, and imaging suggests that these 
foci are often transient [100]. As a result, neither light microscopy nor PCR-based methodologies can 
be used to reliably monitor in vivo infections in real time, and even end-point assays can be uncertain 
[67]. However, it is now clear that non-invasive bioluminescence imaging of mice infected with T. 
cruzi that stably express a firefly luciferase gene can provide a method for following chronic 
infections, if sufficient sensitivity can be achieved [99–101]. The major determinants of sensitivity in 
these situations are the level of expression of the luciferase enzyme, and the wavelength of light 
emitted by oxidation of the luciferin substrate. Since this is an ATP-dependent reaction, only live 
parasites are detected, which is not necessarily the case with PCR. Insertion of a luciferase gene into 
highly expressed ribosomal loci of the parasite solved the first of these issues, and the use of a 
genetically engineered codon-optimised red-shifted luciferase [102] addressed the second. Visible 
light towards the red end of the spectrum (617 nm in this case) has greater tissue penetration due to 
reductions in the absorbance and scattering of the emitted light. Using these systems, chronic T. cruzi 
infections in mice can be monitored for more than one year, with a limit of detection close to 100 
Figure 2. Fexin dazole outperforms benzni f rti ox as a treatment for experimental
Trypanosoma cruzi infections. (A) BALB/c mice er i it bioluminescent T. cruzi CL Brener
strain [99]. At the chronic sta f i f ction (124 days), they were tr ated with benznidazole (BNZ)
or fexi i azole (FXN) (30 mg/kg, orally, once daily) for 5 days (marked by red arrow). Treated mice
were immunosuppressed on days 138, 142 and 146 using cyclophosphamide (200 mg/kg, i.p) (red
lines). Images were acquired using the Lumina II IVIS system (Caliper Life Science) [100]. (B) BALB/c
mice at the acute stage of infection (15 days) were treated with nifurtimox (NFX) or FXN (100 mg/kg,
orally, once daily) for 10 days (red arrow), and then immunosuppressed on days 35, 39 and 43 using
cyclophosphamide (red line). UT, untreated control mice. Heat-maps are on log10 scales and indicate
intensity of bioluminescence from low (blue) to high (red). Full data set available in reference [34].
4. Highly Sensitive In Vivo Bioluminescence Imaging and Its agas isease
Drug Dev lopment Pipeline
Mice have been widely used as experi e t l i hagas disease drug r search. How ver,
during the chronic stage of infection, which is t t r e therapeutics, the p rasite
burden is extremely low, the sites of infection are hig l , nd i aging su ge ts that th se
foci are often transient [100]. s a result, neither light micr scopy nor PCR-bas d methodologies
can be used to reliably monitor in vivo infections in real time, and even end-point assays can be
uncertain [67]. However, it is now clear that non-invasive bioluminescence imaging of mice infected
with T. cruzi that stably express a firefly luciferase gene can provide a method for following chronic
infections, if sufficient sensitivity can be achieved [99–101]. The major determinants of sensitivity in
these situations are the level of expression of the luciferase enzyme, and the wavelength of light emitted
by oxidation of the luciferin substrate. Since this is an ATP-dependent reaction, only live parasites
are detected, which is not necessarily the case with PCR. Insertion of a luciferase gene into highly
expressed ribosomal loci of the parasite solved the first of these issues, and the use of a genetically
engineered codon-optimised red-shifted luciferase [102] addressed the second. Visible light towards
the red end of the spectrum (617 nm in this case) has greater tissue penetration due to reductions in
the absorbance and scattering of the emitted light. Using these systems, chronic T. cruzi infections in
mice can be monitored for more than one year, with a limit of detection close to 100 parasites using
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in vivo imaging [100], and less than 20 parasites when ex vivo imaging is subsequently used to examine
mouse tissue [103]. With in vivo imaging, there is a linear relationship between the parasite burden
(above 1000 parasites) and whole-body bioluminescence intensity [99]. In addition to a central role in
in vivo drug screening (Figure 2), these imaging procedures have provided new insights into infection
dynamics and tissue tropism [100,101,104], disease pathogenesis [53] and vaccine development [105].
The standard experimental model used for drug testing is the BALB/c mouse infected with
the bioluminescent T. cruzi CL Brener strain, a parasite that belongs to the discrete typing unit
(DTU) VI lineage. In terms of replication rate and virulence, the genetically modified strain is
indistinguishable from the parental line [100]. The acute stage infection follows a regular profile
in which the bioluminescence-inferred parasite burden reaches a peak at approximately 14 days
post-infection (Figure 2B). At this time-point, it is brought under control by the adaptive immune
system, resulting in a drop of up to 1000-fold in parasite numbers as the infection transitions to the
chronic stage, approximately 50–60 days post-infection [100]. During the acute stage, parasites infect
all organs and tissues, whereas in the chronic stage, they are mainly confined to the colon, stomach
and skin (Figure 3A). In C3H/HeN mice, infection of skeletal muscle is also a regular feature of the
chronic stage [101,103]. As in humans, T. cruzi infections are generally life-long, and in vivo imaging
has revealed a highly dynamic profile during the chronic stage in which transient bioluminescence
foci appear and disappear over a time period of hours. The precise nature of these foci is unknown,
but they could represent infected phagocytes in the process of being trafficked from sites of persistence
in the mouse to peripheral sites [47].
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Figure 3. Monitoring parasite tropism and drug t r ic Trypanosoma cruz infections using
ex vivo imaging. (A) BALB/c mice were infect iolu inescent T. cruzi CL Brener strain.
Animals were sacrificed at various points ther after, and organs and tissue were removed, ar anged in
a Petri dish as indicated, and immers d in luciferin [10 ]. Biolu i i aging revealed wide
dissemination a d high parasite burden at the peak of the acute stage (14 days post-infection), and the
effect of immune-mediated control f the infection during the transition to the chronic p ase (typically
day 40–60). In this infection model, the predominant long-term sites of parasite persistence are the
colon and/or stomach. Infection of other organs/tissues is more sporadic, although parasites are often
located in the skin [103]. (B) Exploiting ex vivo imaging to assess drug efficacy against chronic T. cruzi
infection. Detailed information on parasite tropism and drug susceptibility can be established by
including the entire carcass and head of the mouse in the imaging process. In the example shown,
benznidazole (BZN) treatment has eliminated detectable parasites. In the nontreated mouse, infection
of the head region was observed (parietal, frontal, zygomatic and lacrimal bones; red arrows).
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This bioluminescence imaging system has now been incorporated into several Chagas disease
drug development programmes [34,52,106]. It can be used to monitor drug efficacy against both acute
and chronic infections (Figure 2A,B, Figure 3B) [34,67], enables several different dosing regimens to be
assessed in parallel, allows tissue-specific differences in drug sensitivity to be investigated, and can be
adapted to study the correlation between drug activity and disease pathology [53]. Typically, when
treatment is complete, the mice are followed for another 10–20 days to determine the extent of any
relapse. They are then immunosuppressed by cyclophosphamide (3 injections, 200 mg/kg i.p., at 3-day
intervals) to facilitate the expansion of any residual parasites to detectable levels (Figure 2A,B) [101].
As a final step, mice are designated as cured/non-cured on the basis of both in vivo and ex vivo imaging.
The sensitivity of this system seems to circumvent many of the issues related to the high false-cure
rate that can be a problem with PCR-based diagnosis, as well as providing valuable insights into
the dynamics of drug activity. In addition, the ability to continuously monitor individual mice in a
non-invasive manner provides more comprehensive data sets, and reduces the number of animals
required for experimentation.
The crucial factor with any experimental model is the reliability with which findings are directly
translatable to human patients. In mice, the infection profile revealed by bioluminescence imaging
closely mirrors that in humans, with a clearly defined acute stage, that transitions to a life-long
chronic infection characterised by an extremely low parasite burden (Figure 2) [100]. This general
trend holds true in a range of mouse models, although there can be some minor variation in the
precise timing of events [101], a situation that also seems to be the case in humans. In terms of drug
efficacy, the bioluminescence mouse model was predictive of the failure of posaconazole to cure human
infections, despite impressive transient reductions in the parasite load [67]. Similar murine experiments
have also demonstrated that benznidazole and nifurtimox have greater curative efficacy in the chronic
stage than in the acute stage [34]. This may simply reflect the much larger number of parasites that
have to be eliminated during acute stage infections. If these findings can be extended to humans,
it suggests that there could be scope to decrease the treatment length and/or the drug dose without
reducing the chronic infection cure rate. As outlined above, preliminary data from the BENDITA
clinical trial [59] suggest that this may be the case, a finding that could have an enormous impact
on patient compliance. Likewise, an on-going clinical trial [35] will provide further information on
predictive value of the bioluminescence model, which was used to demonstrate that fexinidazole has
superior curative properties compared to the current front-line drugs [34]. Murine models coupled with
bioluminescent parasites will also provide a flexible platform for exploring issues such as combination
therapy, so that the relative compound doses can be rapidly optimised before being advanced into
clinical trial [64,65].
5. Concluding Remarks
In recent years, technical advances in several areas of the drug development process have
contributed to a more favourable landscape for improving the therapeutic options available to
treat neglected tropical diseases. In parallel, changes in research practice, accompanied by a more
sympathetic funding environment, have contributed to the establishment of large drug discovery
consortia that take a more systematic and multidisciplinary approach. After many years in which
few therapeutic candidates advanced far along the development pipeline, the outlook for improved
treatments for Chagas disease is looking considerably more favourable.
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